
Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 23.8% at $4.28 Tuesday morning after the company announced the FDA lifted its clinical hold on the company's COVID-19 vaccine study in the US.
"We are pleased to be able to move our clinical program for Covaxin forward, which we hope will bring us closer to offering an alternative Covid-19 vaccine," said Dr. Shankar Musunuri, CEO of Ocugen. "We firmly believe that managing this pandemic requires more than one approach to vaccines, so we are heartened to be able to continue developing our vaccine candidate."